MARKER THERAPEUTICS, INC. Professional Fees
MARKER THERAPEUTICS, INC. (MRKR) reported Professional Fees of $305.42 thousand for the 3-month period ending 2014-09-30, per its 10-Q filed 2014-11-19.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ProfessionalFees · last filed 2014-11-19
- MARKER THERAPEUTICS, INC. professional fees for the quarter ending 2014-09-30 was $305.42K, a 336.70% increase year-over-year.
- MARKER THERAPEUTICS, INC. professional fees for the quarter ending 2014-06-30 was $122.60K, a 3.32% increase year-over-year.
- MARKER THERAPEUTICS, INC. professional fees for the quarter ending 2014-03-31 was $186.24K, a 30.15% decline year-over-year.
- MARKER THERAPEUTICS, INC. professional fees for the quarter ending 2013-09-30 was $69.94K, a 221.45% increase year-over-year.
- MARKER THERAPEUTICS, INC. professional fees for fiscal 2013 was $845.33K, a 72.68% increase from fiscal 2012.
- MARKER THERAPEUTICS, INC. professional fees for fiscal 2012 was $489.54K, a 11.82% increase from fiscal 2011.
- MARKER THERAPEUTICS, INC. professional fees for fiscal 2011 was $437.79K, a 62.72% decline from fiscal 2010.
- MARKER THERAPEUTICS, INC. professional fees for fiscal 2010 was $1.17M.
| Period end | Professional Fees 1 month | Professional Fees 3 month | Professional Fees 3 month as first filed | Professional Fees 6 month | Professional Fees 9 month | Professional Fees 12 month | Professional Fees 143 month | Professional Fees 146 month | Professional Fees 149 month | Professional Fees 152 month | Professional Fees 155 month | Professional Fees 158 month | Professional Fees 161 month | Professional Fees 164 month | Professional Fees 164 month as first filed | Professional Fees 167 month | Professional Fees 170 month | Professional Fees 173 month | Professional Fees 173 month as first filed | Professional Fees 179 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2014-09-30 | $305.42K 10-Q · filed 2014-11-19 | $428.02K derived: sum of 2 quarters · filed 2014-11-19 | $614.26K 10-Q · filed 2014-11-19 | |||||||||||||||||
| 2014-06-30 | $122.60K 10-Q · filed 2014-08-18 | $308.84K 10-Q · filed 2014-08-18 | $6.57M 10-Q · filed 2014-08-18 | |||||||||||||||||
| 2014-03-31 | $186.24K 10-Q/A · filed 2014-05-21 | |||||||||||||||||||
| 2013-12-31 | $845.33K 10-K/A · filed 2014-04-17 | $6.45M 10-Q/A · filed 2014-05-21 | $6.26M 10-K/A · filed 2014-04-17 | |||||||||||||||||
| 2013-09-30 | $69.94K 10-Q · filed 2014-11-19 | $188.60K derived: sum of 2 quarters · filed 2014-11-19 | $455.23K 10-Q · filed 2014-11-19 | $735.90K derived: sum of 4 quarters · filed 2014-11-19 | $5.87M 10-Q · filed 2013-11-19 | |||||||||||||||
| 2013-06-30 | $118.66K 10-Q · filed 2014-08-18 | $385.29K 10-Q · filed 2014-08-18 | $665.96K derived: sum of 3 quarters · filed 2014-08-18 | $687.72K derived: sum of 4 quarters · filed 2014-08-18 | $5.80M 10-Q · filed 2013-08-19 | |||||||||||||||
| 2013-03-31 | $266.63K 10-Q/A · filed 2014-05-21 | $83.66K 10-Q · filed 2013-05-21 | $547.30K derived: sum of 2 quarters · filed 2014-05-21 | $569.06K derived: sum of 3 quarters · filed 2014-05-21 | $682.04K derived: sum of 4 quarters · filed 2014-05-21 | $5.68M 10-Q/A · filed 2013-08-19 | $5.50M 10-Q · filed 2013-05-21 | |||||||||||||
| 2012-12-31 | $280.67K derived: 10-K 12 month − 10-Q 9 month · filed 2013-05-15 | $302.43K derived: sum of 2 quarters · filed 2013-11-19 | $415.41K derived: sum of 3 quarters · filed 2013-11-19 | $489.54K 10-K/A · filed 2014-04-17 | $5.42M 10-K · filed 2013-05-15 | |||||||||||||||
| 2012-09-30 | $21.76K 10-Q · filed 2013-11-19 | $134.74K derived: sum of 2 quarters · filed 2013-11-19 | $208.87K 10-Q · filed 2013-11-19 | $329.52K derived: sum of 4 quarters · filed 2013-11-19 | $5.14M 10-Q · filed 2012-11-19 | |||||||||||||||
| 2012-06-30 | $112.98K 10-Q · filed 2013-08-19 | $187.11K 10-Q · filed 2013-08-19 | $307.76K derived: sum of 3 quarters · filed 2013-08-19 | $343.94K derived: sum of 4 quarters · filed 2013-08-19 | $5.11M 10-Q/A · filed 2012-09-12 | |||||||||||||||
| 2012-04-30 | $7.50K 10-Q/A · filed 2012-09-12 | |||||||||||||||||||
| 2012-03-31 | $74.13K 10-Q/A · filed 2013-08-19 | $194.78K derived: sum of 2 quarters · filed 2013-08-19 | $230.96K derived: sum of 3 quarters · filed 2013-08-19 | $395.90K derived: sum of 4 quarters · filed 2013-08-19 | $5.00M 10-Q · filed 2012-05-21 | |||||||||||||||
| 2011-12-31 | $120.66K derived: 10-K 12 month − 10-Q 9 month · filed 2013-05-15 | $156.83K derived: sum of 2 quarters · filed 2013-05-15 | $321.77K derived: sum of 3 quarters · filed 2013-05-15 | $437.79K 10-K · filed 2013-05-15 | $4.93M 10-K · filed 2012-04-16 | |||||||||||||||
| 2011-09-30 | $36.17K 10-Q · filed 2012-11-19 | $201.12K derived: sum of 2 quarters · filed 2012-11-19 | $317.13K 10-Q · filed 2012-11-19 | $906.90K derived: sum of 4 quarters · filed 2012-11-19 | $4.37M 10-Q · filed 2011-11-21 | |||||||||||||||
| 2011-06-30 | $164.94K 10-Q/A · filed 2012-09-12 | $280.96K 10-Q/A · filed 2012-09-12 | $870.73K derived: sum of 3 quarters · filed 2012-09-12 | $1.04M derived: sum of 4 quarters · filed 2012-09-12 | $4.34M 10-Q · filed 2011-08-22 | |||||||||||||||
| 2011-03-31 | $116.01K 10-Q · filed 2012-05-21 | $705.79K derived: sum of 2 quarters · filed 2012-05-21 | $876.45K derived: sum of 3 quarters · filed 2012-05-21 | $1.15M derived: sum of 4 quarters · filed 2012-05-21 | ||||||||||||||||
| 2010-12-31 | $589.77K derived: 10-K 12 month − 10-Q 9 month · filed 2012-04-16 | $760.43K derived: sum of 2 quarters · filed 2012-04-16 | $1.04M derived: sum of 3 quarters · filed 2012-04-16 | $1.17M 10-K · filed 2012-04-16 | ||||||||||||||||
| 2010-09-30 | $170.66K 10-Q · filed 2011-11-21 | $448.73K derived: sum of 2 quarters · filed 2011-11-21 | $584.56K 10-Q · filed 2011-11-21 | |||||||||||||||||
| 2010-06-30 | $278.07K 10-Q · filed 2011-08-22 | $413.91K 10-Q · filed 2011-08-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |